Organ-on-a-chip: Thumb-sized Organs, Huge Potential For Pharma R&D 25 January 2024 - Discover what impact organ-on-a-chip could have on drug development and how Pharma stakeholders are investing to realise its true potential. Insights
Circular RNA: Could RNA Rings Become Pharma’s New Jewel? 13 November 2023 - Pharma is betting big on circular RNA to be the next generation of therapies. Here is, in a nutshell, why you should keep an eye on this exciting technology. Insights
Larka Advises Motion Equity On Its Acquisition Of Banook 3 November 2023 - Larka is delighted to announce it acted as the buy-side Commercial Due Diligence advisor for Motion Equity Partners—supporting its acquisition of Banook, a leading French Central Service Provider. Merger & Acquisition
Larka Performs 4 Sourcing Processes for Global BioPharma Clients. 23 October 2023 - Leveraging Lensource®, Larka enabled the identification and selection of CRO, CDMO and CMO partners for 4 major Biotech & Pharma clients, including... Tech Ops & Outsourcing
CMO Sourcing Process for Juvisé Pharmaceuticals 15 May 2023 - Juvisé Pharmaceuticals leveraged Larka’s Lensource® solution for the identification, assessment and selection of a Contract Manufacturing Organisation (CMO) partner to supply one of its commercial products. Tech Ops & Outsourcing
Larka Advises Biose Industrie, Acquired by L-GAM & the French State 17 March 2023 - Larka is delighted to announce it acted as the sell-side Vendor Commercial Due Diligence provider to support the sale process of Biose Industrie—a world-leading Contract Development and Manufacturing Organisation (CDMO)—acquired by L-GAM & the French State. Merger & Acquisition
Larka Advises Apax Partners On Its Acquisition Of Porsolt 8 March 2023 - Larka is delighted to announce it acted as the buy-side Commercial Due Diligence advisor for Apax Partners, supporting its acquisition of Porsolt, a leading French Contract Research Organization (CRO). Merger & Acquisition
Larka Supports Albumedix' Sale Process, Acquired by Sartorius 26 October 2022 - Larka is delighted to announce it acted as the sell-side Vendor Commercial Due Diligence provider to support the sale process of Albumedix – a leading recombinant albumin-based solution provider based in Nottingham, UK – acquired by the Sartorius Group. Merger & Acquisition
Larka Advises Keensight on CRO Axxam Acquisition 1 September 2022 - Larka is delighted to announce it acted as the buy-side Commercial Due Diligence provider to support Keensight Capital on its acquisition of a majority stake in Axxam, a global-leading Contract Research Organization (CRO) based in Italy. Merger & Acquisition
Larka Advises Cathay on its Investment in CRO Transcure 31 August 2022 - Larka is thrilled to announce it performed the Commercial Due Diligence to support Cathay Capital’s investment in TransCure bioServices, a global-leading Contract Research Organization (CRO) based in France. Merger & Acquisition
Larka Advises Merieux Equity Partners on its investment in Janvier Labs 26 July 2022 - Larka provides Merieux Equity Partners with a Commercial Due Diligence to support its investment in French BioPharma company Janvier Labs. Merger & Acquisition
Larka Advises Elyan on CRO Oncodesign Acquisition Process 11 July 2022 - Larka provides Elyan Partners with a Commercial Due Diligence to support the acquisition of CRO services Business Unit of Oncodesign, a leading French BioPharma company. Merger & Acquisition
Larka Advises Gimv on CDMO BioConnection Investment Deal 24 May 2022 - Larka provides Gimv with a Technical Due Diligence and Operational Due Diligence to support its investment in leading Dutch bio-CDMO BioConnection. Merger & Acquisition
Interview with: Yana Marmann 25 April 2022 - Fresh out of college and hired amid the COVID-19 pandemic, Yana saw in Larka an opportunity to shape a career within the BioPharma industry while evolving in a fast-paced and exciting environment. Our People
Vendor Due Diligence for Afinum and SHS | evitria 27 July 2021 - Larka is very pleased to announce that it’s M&A Unit performed the Vendor Commercial Due-Diligence to support Afinum’s exit process of evitria, a global leading service provider specialized in transient antibody expression. Merger & Acquisition
Commercial Due Diligence for Keensight Capital | Symeres 7 June 2021 - Larka is very proud to announce that it performed the Commercial-Due-Diligence for Keensight Capital on its acquisition of Symeres. Merger & Acquisition
Commercial Due Diligence for Clean Biologics & Archimed | Biodextris 11 May 2021 - Larka is pleased to announce that it performed the Commercial Due-Diligence for Clean Biologics group – backed by Archimed - on their acquisition of Biodextris. Merger & Acquisition
Olivier Dumortier PhD Appointed as Business Development Manager 12 April 2021 - Prior to joining Larka’s Analysts team two years ago, Olivier did a PhD thesis in Belgium - exploring numerous models of metabolic diseases - then worked on non-coding RNA and regulation of cell metabolism and physiology in Canada and France for over a decade. Our People
Maxime Clarhaut Appointed as Associate 8 April 2021 - Maxime has been working with Larka’s Analyst team for over two years now and keeps proving that dedication, combined with passion for Biotech and Pharma industry, lead to great achievements and value creation for our clients. Our People